Search research articles
Contact Us
Filters
Showing results (301-310 of 502) with videos related to
Page
of 51
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2019
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer
David Planchard, Michael J Boyer, Jong-Seok Lee, et al.
BMC Infectious Diseases
|
October 29, 2021
The burden of COVID-19 infection in a rural Tamil Nadu community
R Isaac, B Paul, M Finkel, et al.
Oncogene
|
April 23, 2008
Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe
S M Sureban, S Ramalingam, G Natarajan, et al.
Journal of Clinical Medicine
|
January 8, 2023
Mobocertinib (TAK-788) in <i>EGFR</i> Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
Maria Rosario Garcia Campelo, Caicun Zhou, Suresh S Ramalingam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 8, 2018
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
Taofeek K Owonikoko, Suzanne E Dahlberg, Gabriel L Sica, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
January 21, 2014
Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer
Seth A Brodie, Ge Li, Adam El-Kommos, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 6, 2024
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology
Jennifer A Marks, Nishant Gandhi, Balazs Halmos, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 1, 2025
EGFR mutation testing across the osimertinib clinical program
Marie Laure Murat-Onana, Suresh S Ramalingam, Pasi A Jänne, et al.
Cancer
|
June 22, 2010
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer
Suresh S Ramalingam, R Donald Harvey, Nabil Saba, et al.
Nature Communications
|
July 21, 2019
Acetylation regulates ribonucleotide reductase activity and cancer cell growth
Guo Chen, Yin Luo, Kurt Warncke, et al.
Page
of 51
Search research articles
Search
Showing results (301-310 of 502) with videos related to
Sort By:
Page
of 51
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2019
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer
David Planchard, Michael J Boyer, Jong-Seok Lee, et al.
BMC Infectious Diseases
|
October 29, 2021
The burden of COVID-19 infection in a rural Tamil Nadu community
R Isaac, B Paul, M Finkel, et al.
Oncogene
|
April 23, 2008
Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe
S M Sureban, S Ramalingam, G Natarajan, et al.
Journal of Clinical Medicine
|
January 8, 2023
Mobocertinib (TAK-788) in <i>EGFR</i> Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
Maria Rosario Garcia Campelo, Caicun Zhou, Suresh S Ramalingam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 8, 2018
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
Taofeek K Owonikoko, Suzanne E Dahlberg, Gabriel L Sica, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
January 21, 2014
Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer
Seth A Brodie, Ge Li, Adam El-Kommos, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 6, 2024
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology
Jennifer A Marks, Nishant Gandhi, Balazs Halmos, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 1, 2025
EGFR mutation testing across the osimertinib clinical program
Marie Laure Murat-Onana, Suresh S Ramalingam, Pasi A Jänne, et al.
Cancer
|
June 22, 2010
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer
Suresh S Ramalingam, R Donald Harvey, Nabil Saba, et al.
Nature Communications
|
July 21, 2019
Acetylation regulates ribonucleotide reductase activity and cancer cell growth
Guo Chen, Yin Luo, Kurt Warncke, et al.
Page
of 51